ArticleAmerican journal of cancer research2025
A high-risk prediction model for endometrial cancer: exploring the synergistic interaction between polycystic ovary syndrome and metabolic syndrome.
Article in American journal of cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the synergistic interaction between polycystic ovary syndrome (PCOS) and metabolic syndrome (MetS) in relation to the risk of endometrial cancer (EC). Additionally, we aimed to develop a clinically applicable, high-risk early-warning model that incorporates these interactive factors, enhancing the precision and clinical utility of EC screening.
methodsWe conducted a retrospective case-control study involving 445 newly diagnosed EC patients and 299 healthy female controls from the First People's Hospital of Changde City, between January 2018 and January 2025. Multivariate logistic regression was used to assess the independent and combined effects of PCOS and MetS on EC risk. A nomogram-based predictive model was developed and validated rigorously using training, internal validation, and external validation cohorts. The model's performance was evaluated based on discrimination (area under the curve [AUC]), calibration (Hosmer-Lemeshow test), and clinical utility (decision curve analysis). The diagnostic performance of our comprehensive model was compared to traditional tumor markers (cancer antigen 125/199, human epididymis protein 4).
resultsLASSO regression identified 14 clinically significant predictors. Logistic regression revealed that HE4 levels, endometrial thickness, and fasting blood glucose were independent risk factors for EC, while high-density lipoprotein was an independent protective factor. The nomogram based on these variables demonstrated excellent discrimination, with AUCs of 0.984 in the training set, 0.987 in the internal validation set, and 0.964 in the external validation set. The integrated risk model significantly outperformed individual markers in diagnostic accuracy across all datasets (P<0.001).
conclusionOur PCOS-MetS interaction-based EC risk prediction model showed robust and consistent performance across multiple validation cohorts. This tool significantly improves early detection accuracy and holds substantial clinical promise, laying the foundation for personalized EC risk management strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.